Controversies about the new antiepileptic drugs;Controversias en torno a los nuevos fármacos antiepilépticos

Revista de Neurologia

Volumn 32, Issue 2, 2001, Pages 165-171

  Serrano Castro, P J ^a  

^a HOSPITAL TORRECÁRDENAS   (Spain)

Author keywords

Clobazam; Controversy; Epilepsy; Gabapentin; Lamotrigine; New drugs; Pharmaco economy; Tiagabine; Topiramate; Vigabatrin

Indexed keywords

ANTICONVULSIVE AGENT;

COST; ECONOMICS; EPILEPSY; HUMAN; QUALITY OF LIFE; REVIEW;

ANTICONVULSANTS; COSTS AND COST ANALYSIS; EPILEPSY; HUMANS; QUALITY OF LIFE;

EID: 0035895379     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.3202.2000224     Document Type: Article

References (4)

1. Privitera MD, Treiman DM, Pledger GW, Sahlroot JT, Handforth A, Linde MS, et al. Dezinamide for partial seizures: results of an n-of-I design trial. Neurology 1994; 44: 1453-8.
2. Anhut H, Satzinger G, von Hodenberg A. Ralitoline. Epilepsy Res Suppl 1991; 3: 141-5.
3. Mattson RH, Williamson PD, Hanahan E. Eterobarb therapy in epilepsy. Neurology 1976; 26: 1014-7.
4. Xue BG, Friend JM, Gee KW. Loreclezole modulates [35S] t-butylbicyclo-phosphorothionate and [3H]flunitrazepam binding via a distinct site on the GABAA receptor complex. Eur J Pharmacol 1996; 300: 125-30.